JP2007513968A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007513968A5 JP2007513968A5 JP2006544003A JP2006544003A JP2007513968A5 JP 2007513968 A5 JP2007513968 A5 JP 2007513968A5 JP 2006544003 A JP2006544003 A JP 2006544003A JP 2006544003 A JP2006544003 A JP 2006544003A JP 2007513968 A5 JP2007513968 A5 JP 2007513968A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- target gene
- composition according
- target
- target site
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000623 proteins and genes Proteins 0.000 claims 29
- 239000008194 pharmaceutical composition Substances 0.000 claims 27
- 210000002569 neuron Anatomy 0.000 claims 19
- 108020004459 Small interfering RNA Proteins 0.000 claims 16
- 210000003205 muscle Anatomy 0.000 claims 16
- 239000004055 small Interfering RNA Substances 0.000 claims 16
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims 11
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims 11
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 claims 11
- 210000003169 central nervous system Anatomy 0.000 claims 7
- 230000000295 complement effect Effects 0.000 claims 7
- 208000004756 Respiratory Insufficiency Diseases 0.000 claims 6
- 230000003828 downregulation Effects 0.000 claims 6
- 230000001939 inductive effect Effects 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 201000004193 respiratory failure Diseases 0.000 claims 6
- 239000003153 chemical reaction reagent Substances 0.000 claims 5
- 230000002222 downregulating effect Effects 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 230000001105 regulatory effect Effects 0.000 claims 4
- 101000741929 Caenorhabditis elegans Serine/threonine-protein phosphatase 2A catalytic subunit Proteins 0.000 claims 3
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 claims 3
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 2
- 208000026072 Motor neurone disease Diseases 0.000 claims 2
- 208000000474 Poliomyelitis Diseases 0.000 claims 2
- 208000034972 Sudden Infant Death Diseases 0.000 claims 2
- 206010042440 Sudden infant death syndrome Diseases 0.000 claims 2
- 230000006399 behavior Effects 0.000 claims 2
- 210000005056 cell body Anatomy 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 210000002161 motor neuron Anatomy 0.000 claims 2
- 208000005264 motor neuron disease Diseases 0.000 claims 2
- 230000000626 neurodegenerative effect Effects 0.000 claims 2
- 208000001797 obstructive sleep apnea Diseases 0.000 claims 2
- 230000000241 respiratory effect Effects 0.000 claims 2
- 230000029058 respiratory gaseous exchange Effects 0.000 claims 2
- 210000001044 sensory neuron Anatomy 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- 210000000278 spinal cord Anatomy 0.000 claims 2
- 208000020431 spinal cord injury Diseases 0.000 claims 2
- 101000611262 Caenorhabditis elegans Probable protein phosphatase 2C T23F11.1 Proteins 0.000 claims 1
- 101000688229 Leishmania chagasi Protein phosphatase 2C Proteins 0.000 claims 1
- 230000000386 athletic effect Effects 0.000 claims 1
- 125000002091 cationic group Chemical group 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52932603P | 2003-12-12 | 2003-12-12 | |
| PCT/US2004/041339 WO2005059135A2 (en) | 2003-12-12 | 2004-12-10 | Treatment of mammals by sirna delivery into mammalian nerve cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007513968A JP2007513968A (ja) | 2007-05-31 |
| JP2007513968A5 true JP2007513968A5 (enExample) | 2008-01-31 |
Family
ID=34699962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006544003A Abandoned JP2007513968A (ja) | 2003-12-12 | 2004-12-10 | 哺乳動物神経細胞へのｓｉＲＮＡのデリバリー |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20050234000A1 (enExample) |
| EP (1) | EP1708756A2 (enExample) |
| JP (1) | JP2007513968A (enExample) |
| CA (1) | CA2548972A1 (enExample) |
| WO (1) | WO2005059135A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2553261C (en) | 2004-01-16 | 2014-03-18 | Stefan Barth | Immunokinases |
| RU2410430C2 (ru) * | 2004-08-31 | 2011-01-27 | Силентис С.А.У. | Способы и композиции для ингибирования экспрессии рецептора p2х7 |
| CA2584459A1 (en) | 2004-10-22 | 2006-04-27 | Universite Laval | Modulation of neuroglia-derived bdnf in the treatment and prevention of pain |
| EP1800695A1 (en) | 2005-12-21 | 2007-06-27 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Immuno-RNA-constructs |
| US8530436B2 (en) | 2007-01-29 | 2013-09-10 | Transderm, Inc. | Methods and compositions for transdermal delivery of nucleotides |
| US20120322861A1 (en) | 2007-02-23 | 2012-12-20 | Barry John Byrne | Compositions and Methods for Treating Diseases |
| US20100221225A1 (en) * | 2007-02-23 | 2010-09-02 | University Of Florida Research Foundation, Inc | Compositions and methods for treating glycogen storage diseases |
| FR2921935B1 (fr) * | 2007-10-05 | 2011-10-28 | Centre Nat Rech Scient | Procede de criblage de composes utilisables pour le traitement de troubles respiratoires |
| US9265843B2 (en) | 2008-03-27 | 2016-02-23 | The Ohio State University | Treatment of metabolic-related disorders using hypothalamic gene transfer of BDNF and compositions therefor |
| WO2010051532A1 (en) * | 2008-10-31 | 2010-05-06 | University Of Chicago | Compositions and methods related to obstructive sleep apnea |
| AU2010229872A1 (en) * | 2009-03-26 | 2011-11-03 | The Regents Of The University Of California | Mesenchymal stem cells producing inhibitory RNA for disease modification |
| EP2696678B1 (en) * | 2011-04-15 | 2019-11-20 | Molecular Transfer, Inc. | Agents for improved delivery of nucleic acids to eukaryotic cells |
| DK3292875T3 (en) | 2012-06-19 | 2020-08-03 | Univ Florida | Compositions and methods for treating diseases |
| EP2986599A1 (en) | 2013-04-17 | 2016-02-24 | Pfizer Inc. | N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases |
| CN116942825A (zh) * | 2023-07-21 | 2023-10-27 | 南通大学 | Cda基因在制备治疗神经轴突损伤相关疾病药物中的应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6265387B1 (en) * | 1995-10-11 | 2001-07-24 | Mirus, Inc. | Process of delivering naked DNA into a hepatocyte via bile duct |
| AU6614398A (en) * | 1997-01-17 | 1998-08-07 | Institut National De La Sante Et De La Recherche Medicale | Adenoviral-vector-mediated gene transfer into medullary motor neurons |
| KR100909681B1 (ko) * | 2000-12-01 | 2009-07-29 | 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. | Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자 |
-
2004
- 2004-12-10 JP JP2006544003A patent/JP2007513968A/ja not_active Abandoned
- 2004-12-10 CA CA002548972A patent/CA2548972A1/en not_active Abandoned
- 2004-12-10 WO PCT/US2004/041339 patent/WO2005059135A2/en not_active Ceased
- 2004-12-10 EP EP04813641A patent/EP1708756A2/en not_active Withdrawn
- 2004-12-10 US US11/009,797 patent/US20050234000A1/en not_active Abandoned
-
2008
- 2008-01-10 US US11/972,376 patent/US20090186844A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007513968A5 (enExample) | ||
| Griesbach et al. | Time window for voluntary exercise–induced increases in hippocampal neuroplasticity molecules after traumatic brain injury is severity dependent | |
| Wang et al. | Selective optogenetic activation of orexinergic terminals in the basal forebrain and locus coeruleus promotes emergence from isoflurane anaesthesia in rats | |
| Guyenet et al. | The retrotrapezoid nucleus and breathing | |
| Subramanian et al. | The midbrain periaqueductal gray changes the eupneic respiratory rhythm into a breathing pattern necessary for survival of the individual and of the species | |
| MX2009012430A (es) | Amidas disustituidas para mejorar las respuestas sinapticas glutamatergicas. | |
| MX2010002890A (es) | 1, 2, 3-triacin -4-onas sustituidas en la posicion 3 y 1, 3- pirimidinonas sustituidas en la posicion 3 para mejorar las respuestas sinapticas glutamatergicas. | |
| WO2009023126A3 (en) | Bicyclic amides for enhancing glutamatergic synaptic responses | |
| Lemes et al. | Vagal afferent control of abdominal expiratory activity in response to hypoxia and hypercapnia in rats | |
| Chen et al. | Chd8 rescued TBI-induced neurological deficits by suppressing apoptosis and autophagy via Wnt signaling pathway | |
| Stein et al. | Brain-derived neurotrophic factor: the neurotrophin hypothesis of psychopathology | |
| Cui et al. | Sleep patterns deteriorate over time in chronic corticosterone-treated rats | |
| US20130164367A1 (en) | Treatment of neurodegenerative disease with creb-binding protein | |
| Lara et al. | Laryngeal effects of stimulation of rostral and ventral pons in the anaesthetized rat | |
| Dong et al. | Astrocytic ERK/STAT1 signaling contributes to maintenance of stress-related visceral hypersensitivity in rats | |
| Mällo et al. | Regulation of extracellular serotonin levels and brain-derived neurotrophic factor in rats with high and low exploratory activity | |
| Xing et al. | Corticostriatal projections relying on GABA levels mediate exercise-induced functional recovery in cerebral ischemic mice | |
| Chen et al. | BDNF overexpression exhibited bilateral effect on neural behavior in SCT mice associated with AKT signal pathway | |
| Kuwaki et al. | Orexin neurons and emotional stress | |
| Ludlow | Motor control and biomechanics of laryngeal and pharyngeal muscles | |
| Monaco et al. | The convergence of glutamate and GABA dysregulation in schizophrenia | |
| Iłżecka | Kinesitherapy in amyotrophic lateral sclerosis | |
| Lin et al. | Inhibition of miR-665 alleviates neuropathic pain by targeting SOCS1 | |
| Matteoli | Categorization of sleep apneas in different mouse models of human diseases | |
| Kyriakoulis et al. | Acid-Sensing Ion Channels in Panic Disorder |